# Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XNW7201 in Subjects With Advanced Solid Tumors

> **NCT03901950** · PHASE1 · COMPLETED · sponsor: **Evopoint Biosciences Inc.** · enrollment: 45 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** XNW7201 tablets

## Key facts

- **NCT ID:** NCT03901950
- **Lead sponsor:** Evopoint Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-01
- **Primary completion:** 2021-12-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2023-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03901950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03901950, "Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XNW7201 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03901950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*